{"id":"W4362588741","doi":"10.1016/s1556-0864(23)00424-0","title":"170P Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; GlaxoSmithKline; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Etoposide; Internal medicine; Phases of clinical research; Oncology; Chemotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001377481,0.0003278341,0.001485476,0.0004603158,0.0001926137,0.00001938345,0.00033601,0.0001756718,0.00003426991],"category_scores_gemma":[0.003178364,0.0002378737,0.0002193301,0.0006585316,0.0002972845,0.0002317949,0.0002340669,0.0006511461,0.000008747964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007160833,"about_ca_system_score_gemma":0.0008201011,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009425232,"about_ca_topic_score_gemma":0.0001149157,"domain_scores_codex":[0.9959491,0.0003559655,0.001457457,0.0004817034,0.001147706,0.0006080088],"domain_scores_gemma":[0.99353,0.001830411,0.001725571,0.0005182477,0.002118931,0.0002768526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6172427,0.04747435,0.03850475,0.001231843,0.004516474,0.007060939,0.02964547,0.0004794637,0.009351549,0.000007958653,0.04422413,0.2002604],"study_design_scores_gemma":[0.1081438,0.5184805,0.3189961,0.002874622,0.002848244,0.000225492,0.02475178,0.0008702602,0.006490413,0.0001896555,0.01547893,0.0006501751],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942628,0.0004271935,0.00007164293,0.00157378,0.0006487197,0.002213771,0.0003896177,0.00004022511,0.0003722662],"genre_scores_gemma":[0.9946352,0.000143254,0.003300543,0.0001242876,0.0005125378,0.00007950411,0.00007204344,0.00006420825,0.001068417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5090989,"threshold_uncertainty_score":0.9700207,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06322569750506297,"score_gpt":0.4574548974330709,"score_spread":0.394229199928008,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}